Format

Send to

Choose Destination
Elife. 2017 Oct 13;6. pii: e31268. doi: 10.7554/eLife.31268.

Metformin extends C. elegans lifespan through lysosomal pathway.

Chen J#1,2, Ou Y#1, Li Y1,2, Hu S1,2, Shao LW1,2, Liu Y1.

Author information

1
State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
2
Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
#
Contributed equally

Abstract

Metformin, a widely used first-line drug for treatment of type 2 diabetes (T2D), has been shown to extend lifespan and delay the onset of age-related diseases. However, its primary locus of action remains unclear. Using a pure in vitro reconstitution system, we demonstrate that metformin acts through the v-ATPase-Ragulator lysosomal pathway to coordinate mTORC1 and AMPK, two hubs governing metabolic programs. We further show in Caenorhabditis elegans that both v-ATPase-mediated TORC1 inhibition and v-ATPase-AXIN/LKB1-mediated AMPK activation contribute to the lifespan extension effect of metformin. Elucidating the molecular mechanism of metformin regulated healthspan extension will boost its therapeutic application in the treatment of human aging and age-related diseases.

KEYWORDS:

AMPK; C. elegans; cell biology; mTOR; metformin

PMID:
29027899
PMCID:
PMC5685485
DOI:
10.7554/eLife.31268
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for eLife Sciences Publications, Ltd Icon for PubMed Central
Loading ...
Support Center